NI-071 (infliximab biosimilar) - Sanofi, Nichi-Iko, Binex, Aprogen
Nichi-Iko: Q2 FY 2015 Results (Nichi-Iko Pharmaceutical Co., Ltd.) - Jan 2, 2016 - Anticipated approval in Japan for inflammatory diseases in September 2016; Anticipated launch in Japan for inflammatory diseases in November 2016; Anticipated initiation of P1 clinical trial in US for inflammatory disease in early 2016; Anticipated regulatory filing in US for inflammatory diseases in 2018; Anticipated approval in US for inflammatory diseases in 2019 
Anticipated BLA • Anticipated Japanese regulatory • Anticipated launch Japan • Anticipated new P1 trial • Biosimilar
http://nichiiko-ir.irbridge.com/en/Library/Presentation/main/0/teaserItems1/0/linkList/00/link/Results%20of%202nd%20Quarter,%20Settlement%20of%20accounts%20supplementary%20material%20(Apr.1%202015%20to%20Sep.30,%202015).pdf
 
Jan 2, 2016
 
.
 
f38b3eba-61b5-472b-ad62-9436fecfd7e6.jpg